[Interval cancers and episode sensitivity in population-based screening programmes for colorectal cancer: a systematic review].
OBJECTIVE
To describe interval cancers (IC) and the sensitivity of colorectal cancer (CRC) screening programmes.


METHODS
A systematic review of the literature was conducted through a MEDLINE (PubMed) search. The search strategy combined the terms 'interval cancer', 'false negative', 'mass screening', 'screening' 'early detection of cancer', 'colorectal cancer' and 'bowel cancer'. Inclusion criteria consisted of population-based screening programmes, original articles written in English or Spanish and publication dates between 1999/01/01 and 2015/02/28. A narrative synthesis of the included articles was performed detailing the characteristics of the screening programmes, the IC rate, and the information sources used in each study.


RESULTS
Thirteen articles were included. The episode sensitivity of CRC screening programmes ranged from 42.2% to 65.3% in programmes using the guaiac test and between 59.1% and 87.0% with the immunochemical test. We found a higher proportion of women who were diagnosed with IC and these lesions were mainly located in the proximal colon.


CONCLUSIONS
There is wide variability in the IC rate in CRC programmes. To ensure comparability between programmes, there is a need for consensus on the working definition of IC and the methods used for their identification and quantification.
Prevención y Control del Cáncer, Instituto Catalán de Oncología-IDIBELL, L'Hospitalet de Llobregat, Barcelona, España.
Xènia
X
Domènech
Prevención y Control del Cáncer, Instituto Catalán de Oncología-IDIBELL, L'Hospitalet de Llobregat, Barcelona, España. Electronic address: mgarcia@iconcologia.net.
Montse
M
Garcia
Prevención y Control del Cáncer, Instituto Catalán de Oncología-IDIBELL, L'Hospitalet de Llobregat, Barcelona, España; Departamento de Enfermería Fundamental y Médico-Quirúrgica, Universidad de Barcelona, L'Hospitalet de Llobregat, Barcelona, España.
Llúcia
L
Benito
Prevención y Control del Cáncer, Instituto Catalán de Oncología-IDIBELL, L'Hospitalet de Llobregat, Barcelona, España; CIBER de Epidemiología y Salud Pública (CIBERESP), España.
Gemma
G
Binefa
Prevención y Control del Cáncer, Instituto Catalán de Oncología-IDIBELL, L'Hospitalet de Llobregat, Barcelona, España.
Carmen
C
Vidal
Prevención y Control del Cáncer, Instituto Catalán de Oncología-IDIBELL, L'Hospitalet de Llobregat, Barcelona, España; CIBER de Epidemiología y Salud Pública (CIBERESP), España.
Núria
N
Milà
Prevención y Control del Cáncer, Instituto Catalán de Oncología-IDIBELL, L'Hospitalet de Llobregat, Barcelona, España; CIBER de Epidemiología y Salud Pública (CIBERESP), España; Departamento de Ciencias Clínicas, Universidad de Barcelona, L'Hospitalet de Llobregat, Barcelona, España.
Víctor
V
Moreno
D000230:Adenocarcinoma / Q000175:diagnosis* / Q000453:epidemiology; D019985:Benchmarking; D003113:Colonoscopy; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000453:epidemiology; D055088:Early Detection of Cancer; D005188:False Negative Reactions; D005260:Female; D006138:Guaiac; D006801:Humans; D007120:Immunochemistry; D008297:Male; D008403:Mass Screening; D009780:Occult Blood; D012680:Sensitivity and Specificity; D013997:Time Factors
D006138:Guaiac
Adverse effects; Colorectal neoplasms; Cribado; Cáncer de intervalo; Efectos adversos; Interval cancer; Mass screening; Neoplasias colorrectales